Jay Olson analyst OPPENHEIMER

Currently out of the existing stock ratings of Jay Olson, 333 are a BUY (92.24%), 27 are a HOLD (7.48%), 1 are a SELL (0.28%).

Jay Olson

Work Performance Price Targets & Ratings Chart

Analyst Jay Olson, currently employed at OPPENHEIMER, carries an average stock price target met ratio of 45.68% that have a potential upside of 32.94% achieved within 173 days.

Jay Olson’s has documented 780 price targets and ratings displayed on 52 stocks. The coverage is on Healthcare, Industrials, Financial Services sectors.

Most recent stock forecast was given on MDGL, Madrigal Pharmaceuticals at 09-Oct-2025.

Wall Street Analyst Jay Olson

Analyst best performing recommendations are on CINC (CINCOR PHARMA).
The best stock recommendation documented was for PRTA (PROTHENA PLC) at 6/1/2021. The price target of $45 was fulfilled within 10 days with a profit of $17.56 (63.99%) receiving and performance score of 63.99.

Average potential price target upside

ACAD ACADIA Pharmaceuticals AMGN Amgen BCYC Bicycle Therapeutics Ltd BIIB Biogen CBAY Cymabay Therapeu CRSP Crispr Therapeutics AG EDIT Editas Medicine FREQ Frequency Therapeutics ICPT Intercept Pharmaceuticals MRTX Mirati Ther NBIX Neurocrine Biosciences NTLA Intellia Therapeutics PRTA Prothena plc PTLA Portola Pharmaceuticals SAGE Sage Therapeutic SGEN Seagen SRRA Sierra Oncology TXMD TherapeuticsMD ENTA Enanta Pharmaceuticals AXON Axon Enterprise AYLA Ayala Pharmaceuticals  DNLI Denali Therapeutics ETN Eaton PLC EXEL Exelixis FOCS Focus Financial Partners INCY yte JSPR Jasper Therapeutics KRTX Karuna Therapeutics MDGL Madrigal Pharmaceuticals NKTR Nektar Therapeutics BIVI Biovie CINC CinCor Pharma ETNB 89bio CGTX Cognition Therapeutics MDCO The Medicines Company RLMD Relmada Therapeutics RVMD Revolution Medicines VKTX Viking Therapeutics VYGR Voyager Therapeutics MRNS Marinus Pharmaceuticals GLTO Galecto  INO Inovio Pharmaceuticals IONS Ionis Pharmaceuticals STRO Sutro Biopharma TERN Terns Pharmaceuticals QTTB Q32 Bio CNAT Conatus Pharmaceuticals INDP Indaptus Therapeutics MDWD Mediwound Ltd MNKD MannKind Corp NTEC Intec Pharma Ltd IMRX Immuneering Corp

Analyst name

Rating

Current price target

Potential Upside

Previous price target

Date

Price targets met ratio

Average potential upside

Average Days to Hit Target

Performance score

Buy

$33

$10.98 (49.86%)

$34

1 months 1 days ago
(28-Sep-2025)

8/13 (61.54%)

$11.68 (54.78%)

113

Buy

$28

$5.98 (27.16%)

$30

1 months 6 days ago
(23-Sep-2025)

0/10 (0%)

$6.74 (31.70%)

Buy

$39

$16.98 (77.11%)

$35

1 months 19 days ago
(10-Sep-2025)

7/12 (58.33%)

$14.8 (61.16%)

671

Buy

$39

$16.98 (77.11%)

$32

1 months 21 days ago
(08-Sep-2025)

1/5 (20%)

$14.16 (57.00%)

349

Hold

$24

$1.98 (8.99%)

$23

2 months 23 days ago
(06-Aug-2025)

10/13 (76.92%)

$-0.4 (-1.64%)

157

Show more analysts

To gain access for the analyst/ stock price target chart please use a computer

Which stock is Jay Olson is most bullish on?

Potential upside of $168.5 has been obtained for MDGL (MADRIGAL PHARMACEUTICALS)

Which stock is Jay Olson is most reserved on?

Potential downside of -$0.02 has been obtained for ACAD (ACADIA PHARMACEUTICALS)

What Year was the first public recommendation made by Jay Olson?

On 2015

To continue looking at which analysts cover the stock please register to the basic or advanced membership

What is AnaChart?